Evaluation of antiaggregatory activity of flavonoid aglycone series
© Bojićć et al; licensee BioMed Central Ltd. 2011
Received: 15 March 2011
Accepted: 11 July 2011
Published: 11 July 2011
Among natural compounds, present in every day diet, flavonoids have shown beneficial effect in prevention of cardiovascular diseases that can be attributed, at least partially to the described antiaggregatory activity i.e. antiplatelet effects of flavonoids. Due to the ever increasing pharmacological interest in antiplatelet agents a systematic experimental evaluation of large flavonoid series is needed.
A set of thirty flavonoid aglycones has been selected for the evaluation. All measurements of aggregation were done under standardized and firmly controlled in vitro conditions. The whole blood samples, multiple platelet functional analyzer and adenosine diphosphate (ADP) as a weak agonist of aggregation were selected for this purpose.
The results were expressed as minimal concentration of flavonoid that can significantly lower the platelet aggregation compared to the corresponding untreated sample (minimal antiaggregatory concentration - MINaAC). All analyzed flavonoids exhibited antiaggregatory activity MINaAC ranging from 0.119 μM to 122 μM, while the most potent representatives were 3,6-dihydroxyflavone (0.119 μM) and syringetin (0.119 μM).
Measurable antiplatelet activity established at submicromolar flavonoid concentrations suggests that even a dietary consumption of some flavonoids can make an impact on in vivo aggregation of platelets. These findings also point out a therapeutical potential of some flavonoids.
Flavonoid antiplatelet activity can be attributed to the increased production of prostacyclin by endothelian cells. Prostacyclin decreases aggregation via synthesis of cAMP - increased concentration of cAMP inhibits the expression of platelet GPIIb/IIIa receptors . In vitro inhibition of cyclooxygenase, lipooxygenase, thyrosine kinase, phosphodiesterase or phospholipase by flavonoids has also been documented and connected to their antiplatelet activity [8–12]. Although different possible mechanisms have been analyzed a unique mechanism of antiaggregatory activity of flavonoids has not been undoubtedly proven yet.
There are also doubts about antiaggregatory effectiveness in vivo, due to high concentrations of flavonoids that have been used in experiments in vitro (10 - 1000 μM) that can not be reached in vivo after oral intake (0.6 μM) .
Most of the research on antiaggregatory effect of flavonoids has been done using Born spectrophotometric aggregometry. A major disadvantage of this method is usage of platelets rich plasma (PRP) instead of whole blood. Furthermore, most authors tested a range or even a single concentration of flavonoids, and often the series of tested flavonoids were small, thus limiting the overall interpretation of the results [9, 14–18]. Finally, influence of biological variability has not been evaluated.
In this paper our objective was to analyse antiaggregatory effect of a relatively large set consisting of 30 flavonoid aglycons. Instead of Born method impedance aggregometry has been chosen as it enables usage of whole blood. This method reduces problems related to lack of standardization of PRP preparation and provides insight to possible interactions of flavonoids with blood components other than platelets. Biological triplicates of all experiments have been made on blood samples taken from three different blood donors. Along with the statistical evaluation of difference between treated and untreated samples this approach clearly minimizes chance effects caused by large biological variability.
Antiaggregatory activity of flavanons
Antiaggregatory activity of flavones
Antiaggregatory activity of flavanonols
Antiaggregatory activity of isoflavones
ADP was obtained from Dynabyte, Germany, and saline-CaCl2 (0.003 M CaCl2 in 0.9% NaCl) from Croatian Institute of Transfusion Medicine, Croatia.
Freshly taken citrated blood (final citrate concentration 0.129 mol/L) was used for the measurement of aggregation each time from three different healthy volunteers per each flavonoid sample. This work was approved by Ethical comities of Croatian Institute of Transfusion Medicine and Faculty of Pharmacy and Biochemistry, University of Zagreb. A total number of 100 volunteers participated in this research. All volunteers gave informed written consent.
Platelet aggregation was analyzed by Multiplate® analyzer (Dynabyte, Germany). Generic procedure was used: 300 μL of blood was incubated for 6 minutes with 20 μL flavonoid solution and 300 μL of saline-CaCl2 preheated at 37°C. For negative control (untreated sample) 20 μL of solvent - DMSO was used (final concentration 3%). Aggregation cascade was induced by adding 20 μL of adenosine diphosphate reagent (ADPtest; final concentration of ADP 6.5 μM). Aggregation was measured for 6 minutes and expressed as area under curve in arbitrary units (AU).
Results and Discussion
All analyzed flavonoids exhibited antiaggregatory activity with MINaAC ranging from 119 nM to 122 μM.
Pinocembrine-7-methylether has lower MINaAC than pinocembrin, thus methylated derivates of flavanons have greater antiaggregatory effect. Most potent flavanones are p-O-methylated derivates at B-ring (Table 1).
Monohydroxylated flavones are most potent if substituted at the position 6 of the A-ring (6-hydroxyflavone, Table 2). However, most naturally occurring flavonoids are hydroxylated at position 7 (7-hydroxyflavone), thus having lower antiaggregatory effect. Increase in number of hydroxyl groups does not influence antiaggregatory effect (flavone, chrysin, apigenin). Methylation increases antiaggregatory effect, the same as it does in case of flavones (tectochrysin > chrysin). If the flavone has more than four substituents the activity decreases, even if methylated (diosmetin, luteolin, tangeretin).
Generally hydoxylated flavanons have greater antiaggregatory effect than flavones (pinocembrin > chrysin), opposite to methylated derivates (hesperetin > diosmetin, isosakuranetin > acacetin, pinocembrin-7-methylether = tectochrysin).
Comparing monohydroxylated flavanonols to monohydroxylated flavones antiaggregatory effect is higher (3,6-dihydroxyflavone > 6-hydroxyflavone, 3,7-dihydroxyflavone > 7-hydroxyflavone). As it is the case with flavones, increase in number of substituents (four and more) decreases, while methylation increases antiaggregatory effect (syringetin > rhamnetin > quercetin, Table 3).
Isoflavonoids are less potent antiaggregatory agents, but the same as for flavonoids applies: increase in hydroxylation decreases while methylation increases antiaggregatory effect (Table 4). This is probably due to greater volume and higher lipophilicity of the methyl radical (V = 37.15, π = -0.09) compared to hydroxyl group (V = 11.79, π = -0.74). Higher lipophilicity can lead to significant interactions with the platelet's membrane by increasing rigidity. The membrane is stabilized and the appearance of the receptors - integrins e.g. GPIIa/IIIb at the platelet surface is limited [19–21].
Epicatechin, present in wine, was the only catechin analyzed (Table 5). It has greater antiaggregatory effect compared to flavone and flavanonol parallels, namely luteolin and quercetin.
double bond at the position C2-C3 increases activity for hydroxylated derivates, but decreases activity for methylated derivates at the ring A and B,
hydroxyl group at the position C3 increases antiaggregatory activity,
transfer of B ring from C2 to C3 decreases activity (isoflavonoids),
absence of carbonyl group at the position C4 increases activity,
most potent flavonoids are substituted at the position C6 of the ring A,
O-methylation of the rings A and B increases activity,
if the rings A and B have 4 and more radicals activity decreases.
The results of antiaggregatory effect of flavonoids were compared to clopidogrel which acts as antagonist of ADP and serves as positive control in the experiment (Table 5). Although results for clopidogrel are comparable to results of the most potent flavonoids 3,6-dihydroxyflavone and syringetin, this should be interpreted with caution. Clopidogrel is a pro-drug whose metabolic activation to some extent can occur in vitro as main enzyme responsible for activation CYP2C19 is present in different tissues including the blood .
Dell'Agli et al. reported that inhibitory effect on platelet aggregation (induced by thrombin) of 10 μM concentration of individual compound followed the order: luteolin, quercetin and apigenin, the last being inactive . In our study MINaAC followed the other arrangement: apigenin (3.815 μM), luteolin (7.629 μM), quercetin (15.259 μM), using ADP to induce aggregation.
Comparing the sets of flavonoids analyzed in our research to the work of Navarro-Nuñez et al. where antigreggatory effect was expressed as percentage of inhibition of SQ 29548 binding to thromboxane A2 (TxA2) receptor, apigenin was the most potent antagonist of aggregation . Thus, it achieves antiaggregatory effect both through antagonism of thromboxane A2 receptors as well as ADP receptors. However, genistein was next potent antagonist of TxA2 receptors, contrary to our research where isoflavonoids showed lower antagonism to ADP receptors compared to other classes of flavonoids. Hesperetin has MINaAC of 1.907 μM, ten to thirty times lower than reported by Jin et al., as expected due to usage of strong agonists of aggregation (collagen, arachidonic acid) .
where M represents average molar mass of flavonoid being 300 g/mol and V total blood volume of 5 L.
The most potent flavonoids cause minimal antiaggregatory effect in even lower concentrations: 3,6-dihyroxyflavone, syringetin (MINaAC = 0.119 μM), 6-hyroxyflavone, pinocembrin-7-methylether, tectochrysin, rhamnetin and isosakuranetin (MINaAC = 0.954 μM). These levels of flavonoids in serum have been experimentally confirmed for the most commonly consumed flavonoids: hesperetin and naringenin from orange juice, and epi/catechins from coco and green tea - ranging from 0.01 to 1.1 μM for individual flavonoid [26–29]. This is contrary to findings of Janssen et al. that flavonoids are active in concentrations that can not be achieved in vivo .
This work provides insight in the antiaggregatory activity of a relatively large set of flavonoid aglycons measured by standardized impendance aggregometry in whole blood against ADP as an inductor. SAR of flavonoids shows that increase in the number of hydroxyl groups at the rings A and B, decreases activity. On the other hand, if O-methyl groups are introduced activity increases. This indicates that the size/volume and lipophilicity of the radical is important factor, which should be confirmed in further QSAR prediction studies.
The results obtained suggest that even a daily consumption of flavonoids can effect aggregation of platelets. As flavonoids are ubiquitous substances in plants, this work can serve as source of information for further assessment of food influence on antiaggregation/anticoagulation treatment.
This work was supported by the Ministry of Science, Education and Sports of the Republic of Croatia (project No. 006-0061117-1237 - MMŠ).
- Sweetman S: Martindale: The Complete Drug Reference. 2011, London: Pharmaceutical PressGoogle Scholar
- de Lange DW, Verhoef S, Gorter G, Kraaijenhagen RJ, van de Wiel A, Akkerman JW: Polyphenolic grape extract inhibits platelet activation through PECAM-1: an explanation for the French paradox. Alcohol Clin Exp Res. 2007, 31: 1308-1314. 10.1111/j.1530-0277.2007.00439.x.View ArticlePubMedGoogle Scholar
- Leifert WR, Abeywardena MY: Cardioprotective actions of grape polyphenols. Nutr Res. 2008, 28: 729-737. 10.1016/j.nutres.2008.08.007.View ArticlePubMedGoogle Scholar
- Sumpio BE, Cordova AC, Berke-Schlessel DW, Qin F, Chen QH: Green tea, the "Asian paradox," and cardiovascular disease. J Am Coll Surg. 2006, 202: 813-825. 10.1016/j.jamcollsurg.2006.01.018.View ArticlePubMedGoogle Scholar
- Medić-Šarić M, Rastija V, Bojić M, Maleš Ž: From functional food to medicinal product: systematic approach in analysis of polyphenolics from propolis and wine. Nutr J. 2009, 8: 33-10.1186/1475-2891-8-33.View ArticlePubMedPubMed CentralGoogle Scholar
- Akhlaghi M, Bandy B: Mechanisms of flavonoid protection against myocardial ischemia-reperfusion injury. J Mol Cell Cardiol. 2009, 46: 309-317. 10.1016/j.yjmcc.2008.12.003.View ArticlePubMedGoogle Scholar
- Lill G, Voit S, Schrör K, Weber AA: Complex effects of different green tea catechins on human platelets. FEBS Lett. 2003, 546: 265-270. 10.1016/S0014-5793(03)00599-4.View ArticlePubMedGoogle Scholar
- Pignatelli P, Di Santo S, Buchetti B, Sanguigni V, Brunelli A, Violi F: Polyphenols enhance platelet nitric oxide by inhibiting protein kinase C-dependent NADPH oxidase activation: effect on platelet recruitment. FASEB J. 2006, 20: 1082-1089. 10.1096/fj.05-5269com.View ArticlePubMedGoogle Scholar
- Dell'Agli M, Maschi O, Galli GV, Fagnani R, Dal Cero E, Caruso D, Bosisio E: Inhibition of platelet aggregation by olive oil phenols via cAMP-phosphodiesterase. Br J Nutr. 2008, 99: 945-951.View ArticlePubMedGoogle Scholar
- Freedman JE, Parker C, Li L, Perlman JA, Frei B, Ivanov V, Deak LR, Iafrati MD, Folts JD: Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Circulation. 2001, 103: 2792-2798.View ArticlePubMedGoogle Scholar
- Guerrero JA, Lozano ML, Castillo J, Benavente-García O, Vicente V, Rivera J: Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor. J Thromb Haemost. 2005, 3: 369-376. 10.1111/j.1538-7836.2004.01099.x.View ArticlePubMedGoogle Scholar
- Nakahata N: Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther. 2008, 118: 18-35. 10.1016/j.pharmthera.2008.01.001.View ArticlePubMedGoogle Scholar
- Janssen K, Mensink RP, Cox FJ, Harryvan JL, Hovenier R, Hollman PC, Katan MB: Effects of the flavonoids quercetin and apigenin on hemostasis in healthy volunteers: results from an in vitro and a dietary supplement study. Am J Clin Nutr. 1998, 67: 255-262.PubMedGoogle Scholar
- Weng JR, Chan SC, Lu YH, Lin HC, Ko HH, Lin CN: Antiplatelet prenylflavonoids from Artocarpus communis. Phytochemistry. 2006, 67: 824-829. 10.1016/j.phytochem.2006.01.030.View ArticlePubMedGoogle Scholar
- Heptinstall S, May J, Fox S, Kwik-Uribe C, Zhao L: Cocoa flavanols and platelet and leukocyte function: recent in vitro and ex vivo studies in healthy adults. J Cardiovasc Pharmacol. 2006, 47 (Suppl 2): S197-205.View ArticlePubMedGoogle Scholar
- Hubbard GP, Wolffram S, Lovegrove JA, Gibbins JM: Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. J Thromb Haemost. 2004, 2: 2138-2145. 10.1111/j.1538-7836.2004.01067.x.View ArticlePubMedGoogle Scholar
- Jin YR, Han XH, Zhang YH, Lee JJ, Lim Y, Chung JH, Yun YP: Antiplatelet activity of hesperetin, a bioflavonoid, is mainly mediated by inhibition of PLC-gamma2 phosphorylation and cyclooxygenase-1 activity. Atherosclerosis. 2007, 194: 144-152. 10.1016/j.atherosclerosis.2006.10.011.View ArticlePubMedGoogle Scholar
- Pignatelli P, Pulcinelli FM, Celestini A, Lenti L, Ghiselli A, Gazzaniga PP, Violi F: The flavonoids quercetin and catechin synergistically inhibit platelet function by antagonizing the intracellular production of hydrogen peroxide. Am J Clin Nutr. 2000, 72: 1150-1155.PubMedGoogle Scholar
- Furusawa M, Tsuchiya H, Nagayama M, Tanaka T, Nakaya K, Iinuma M: Anti-platelet and membrane-rigidifying flavonoids in brownish scale of onion. J Health Sci. 2003, 49: 475-480. 10.1248/jhs.49.475.View ArticleGoogle Scholar
- Hendrich AB: Flavonoid-membrane interactions: possible consequences for biological effects of some polyphenolic compounds. Acta Pharmacol Sin. 2006, 27: 27-40. 10.1111/j.1745-7254.2006.00238.x.View ArticlePubMedGoogle Scholar
- O'Malley BA: Primary Hemostasis. Clinical Laboratory Hematology. Edited by: McKenzie SB, Williams JL. 2010, New York: Pearson, 612-638. 2Google Scholar
- Božina N, Bradamante V, Lovrić M: Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol. 2009, 60: 217-242.PubMedGoogle Scholar
- Navarro-Núñez L, Castillo J, Lozano ML, Martínez C, Benavente-García O, Vicente V, Rivera J: Thromboxane A2 receptor antagonism by flavonoids: structure-activity relationships. J Agric Food Chem. 2009, 57: 1589-1594. 10.1021/jf803041k.View ArticlePubMedGoogle Scholar
- Hertog MG, Hollman PC, Katan MB, Kromhout D: Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr Cancer. 1993, 20: 21-29. 10.1080/01635589309514267.View ArticlePubMedGoogle Scholar
- Hollman PC, de Vries JH, van Leeuwen SD, Mengelers MJ, Katan MB: Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr. 1995, 62: 1276-1282.PubMedGoogle Scholar
- Stalmach A, Mullen W, Steiling H, Williamson G, Lean ME, Crozier A: Absorption, metabolism, and excretion of green tea flavan-3-ols in humans with an ileostomy. Mol Nutr Food Res. 2010, 54: 323-334. 10.1002/mnfr.200900194.View ArticlePubMedGoogle Scholar
- Gardana C, Guarnieri S, Riso P, Simonetti P, Porrini M: Flavanone plasma pharmacokinetics from blood orange juice in human subjects. Br J Nutr. 2007, 98: 165-172. 10.1017/S0007114507699358.View ArticlePubMedGoogle Scholar
- Bredsdorff L, Nielsen IL, Rasmussen SE, Cornett C, Barron D, Bouisset F, Offord E, Williamson G: Absorption, conjugation and excretion of the flavanones, naringenin and hesperetin from alpha-rhamnosidase-treated orange juice in human subjects. Br J Nutr. 2010, 103: 1602-1609. 10.1017/S0007114509993679.View ArticlePubMedGoogle Scholar
- Mullen W, Archeveque MA, Edwards CA, Matsumoto H, Crozier A: Bioavailability and metabolism of orange juice flavanones in humans: impact of a full-fat yogurt. J Agric Food Chem. 2008, 56: 11157-11164. 10.1021/jf801974v.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.